Opinion

Video

Addressing Remaining Unmet Needs in mCRPC

Author(s):

Evan Yu, MD ,Jack R. Andrews, MD

Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • What is one key unmet need or clinical utility in the treatment of mCRPC that future trials should address?
      Related Videos
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      NMIBC Maintenance Therapy: Timing, Dosing, and Follow-Up
      1 expert is featured in this series.
      BRCA Mutations in mHSPC: Impact on Therapy Selection
      1 expert is featured in this series.
      Formulations, Food, and Frequency: Optimizing Absorption and Tolerability in Daily Practice
      Defining and Managing BCG-Unresponsive NMIBC
      Defining and Managing BCG-Unresponsive NMIBC
      1 expert is featured in this series.
      Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
      1 expert is featured in this series.
      The Incidence of Prostate Cancer and Risk of Progression in Black Men
      2 experts are featured in this series.
      The Biggest Challenges in Distinguishing ccRCC From Benign Renal Masses
      2 experts are featured in this series.
      The Evolvement of Imaging in ccRCC
      1 expert in this video
      Comparing Trials Studying Treatment Intensification In mHSPC
      1 expert in this video
      Impact of Robotic Procedures and Apps on Clinic Efficiency
      Related Content
      Skyler Howell, MD | Credit: X.com
      April 28th 2025

      AUA 2025: GLP-1 RAs could improve sperm count in overweight men

      Patrick Campbell
      New research reveals GLP-1 receptor agonists may enhance sperm counts in overweight men.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Pablo Suarez, MS-4 | Credit: UCSF
      April 26th 2025

      Drinking water contaminants could increase risk of kidney stones, study finds

      Patrick Campbell
      New research links higher drinking water contaminants to increased kidney stone risk.
      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD
      May 2nd 2025

      Pearls & Perspectives: Understanding and addressing priapism, with Serge Carrier, MD, and Gregory Broderick, MD

      Amy M. Pearlman, MD
      Experts discuss urgent priapism management strategies, emphasizing timely intervention and collaboration for optimal patient outcomes.
      Stacy Loeb, MD, MSc, PhD | Credit: NYU Langone Health
      April 26th 2025

      TikTok, social media does more harm than good for prostate cancer education

      Patrick Campbell
      Social media spreads significant misinformation about prostate cancer. Experts urge clinicians to provide trusted information sources.
      US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
      February 4th 2025

      FDA Updates in Urology: January 2025

      Patrick Campbell
      A recap of the FDA submissions and regulatory decisions in urology from January 2025.
      © 2025 MJH Life Sciences

      All rights reserved.